14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BIIB vs ADVM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Adverum Biotechnologies, Inc. (ADVM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BIIB carries a Unified Composite Score of 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin), whereas ADVM carries 62.4/100 (BUY) at $4.36 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While ADVM currently prints a higher short-term Unified Composite Score (62.4/100 BUY vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 0.0% operating margin) and revenue trajectory (+10.6% vs. -70.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BIIB vs ADVM. Trailing 12-month operating profitability (BIIB 23.5% vs ADVM 0.0%) and valuation multiples (BIIB 15.6x vs ADVM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Biological Products, (No Disgnostic Substances) Operator
Competes within the Biological Products, (No Disgnostic Substances) value chain with $91.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BIIB vs ADVM Key Questions & Quantitative Answers
As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Adverum Biotechnologies, Inc. (ADVM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BIIB carries a Unified Composite Score of 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin), whereas ADVM carries 62.4/100 (BUY) at $4.36 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ADVM currently prints a higher short-term Unified Composite Score (62.4/100 BUY vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 0.0% operating margin) and revenue trajectory (+10.6% vs. -70.0% YoY).
BIIB leads the Growth & Scale pillar: BIIB posts +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin), compared with ADVM at -70.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BIIB generates $10.3B in USD-normalized revenue versus N/A for ADVM. In operating R&D and SG&A reinvestment, BIIB deploys 52.3% of Rev ($5.39B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ADVM.
BIIB screens cheaper on headline valuation multiples. BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin), whereas ADVM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BIIB (1.9% ROE) versus ADVM (-417.8% ROE) capital efficiency.
In options market volatility and institutional positioning, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk). By comparison, ADVM carries 30.2% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 17% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.